SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT00222677

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.

To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism

NCT00222677 Venous Thromboembolism Deep Venous Thrombosis Pulmonary Embolism Atherosclerosis
MeSH: Thrombosis Atherosclerosis Thromboembolism Embolism Venous Thromboembolism Pulmonary Embolism Venous Thrombosis
HPO: Atherosclerosis Deep venous thrombosis Pulmonary embolism Thromboembolism Type IV atherosclerotic lesion Venous thrombosis

1 Interventions

Name: aspirin

Description: 100 mg daily

Type: Drug


Primary Outcomes

Measure: recurrence of VTE and/or VTE related death

Time: at least 24 months per patient

Secondary Outcomes

Measure: recurrent VTE+ death; cardiovascular events, bleeding events, critical ischemia of the lower limbs, mesenteric infarction, all cause mortality and newly diagnosed cancer

Time: at least 24 months per patient

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 G21210A

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A ---

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A --- --- G21210A ---



HPO Nodes


HPO:
Atherosclerosis
Genes 64
NPC1 COL3A1 TGFB2 TGFB3 TGFBR1 LDLRAP1 TGFBR2 HGD TGFBR3 MFAP5 ANGPTL6 ABCA1 MYH11 LIPC FBN1 ZMPSTE24 CSF2RA MYLK CSF2RB GLB1 LMNA ALMS1 SC5D CYP7A1 LOX ENPP1 MAT2A FOS KCNJ5 ESR1 CYP27A1 ACTA2 AGPAT2 AGXT WRN ANTXR1 OAS1 APOA1 NPC2 SMPD1 APOB CAVIN1 BSCL2 ELN PRKG1 CAV1 LCAT APOE PPARG ENG TNXB SERPIND1 LDLR BANF1 ABCC6 ABCG5 ABCG8 GGCX NOTCH3 ZNF687 SMAD3 PCSK9 CEP19 FOXE3
Deep venous thrombosis
Genes 12
THBD F2 PIEZO1 PROC F5 PROS1 SERPIND1 PMM2 SERPINC1 F9 AKT1 PLAT
Pulmonary embolism
Genes 48
MPL IL10 CD55 JAK2 AGGF1 TET2 IL12A SERPINC1 CCR1 UBAC2 TRNF AKT1 C4A TRNH TRNL1 GNAQ TRNQ PIGA ACVRL1 TRNS1 TRNS2 COX1 PTEN COX2 GDF2 HLA-B COX3 TRNW FAS F2 ENG ERAP1 PLP1 CBS IL12A-AS1 KLRC4 KCNJ5 MEFV IL23R ND1 STAT4 PROC SMAD4 ND4 PROS1 TLR4 ND5 ND6
Thromboembolism
Genes 14
F2 JAK2 PRKAR1A ADA2 INHBA KCNQ1 EPOR HRG CBS SERPINC1 FCGR2C MMACHC PRDX1 PIGA
Type IV atherosclerotic lesion
Genes 1
APOE
Venous thrombosis
Genes 74
MPL IL10 JAK2 TET2 IL12A EPOR MET PRSS1 USP8 PRSS2 SAA1 THBD PDE4D PRTN3 THPO HLA-B SPINK1 SH2B3 PDGFRA ERAP1 HLA-DPA1 CALR IL12A-AS1 HLA-DPB1 PIEZO1 CFTR TLR4 CTRC FGA CD55 FGB PRKAR1A AGGF1 CDH23 CPA1 SERPINC1 CASR CCR1 UBAC2 AKT1 PTPN22 PLAT C4A CTLA4 GNAQ IDH1 FGG IDH2 CTNNB1 ACVRL1 PTEN GDF2 FAS F2 HBB ENG F5 CBS SERPIND1 KLRC4 F9 PTH1R MEFV IL23R NOTCH1 PGM1 TP53 STAT4 KIF11 PROC SMAD4 PROS1 PMM2 PIGM